{"filing":{"accession_number":"0001104659-26-074338","cik":"0001583648","ticker":"PVLA","company_name":"PALVELLA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"tm2618003d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583648/000110465926074338/tm2618003d1_8k.htm"},"events":[{"id":11223,"run_id":9842,"accession_number":"0001104659-26-074338","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Palvella Therapeutics held its Annual Meeting on June 16, 2026, with stockholders voting on six proposals: election of three Class III directors (Jenkins, Davis, Doux), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, advisory frequency vote on compensation (approved annually), approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 750,000, and adjournment authority. All proposals passed.","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7760,"accession_number":"0001104659-26-074338","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 750,000, which is a compensatory arrangement affecting equity grants available to officers and directors. This is a material modification to the equity compensation framework and falls squarely within exec_compensation rather than routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:31:18.630711+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7761,"accession_number":"0001104659-26-074338","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder voting results from Palvella Therapeutics' Annual Meeting held on June 16, 2026. The filing presents final vote tallies for six proposals: election of Class III directors (Jenkins, Davis, Doux), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, advisory frequency vote on compensation (approved annually), approval of equity plan amendment increasing authorized shares by 750,000, and adjournment authority. All proposals passed. This is material as it reflects stockholder decisions on governance, auditor selection, and equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:31:18.630711+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7760,"accession_number":"0001104659-26-074338","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 750,000, which is a compensatory arrangement affecting equity grants available to officers and directors. This is a material modification to the equity compensation framework and falls squarely within exec_compensation rather than routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:31:18.630711+00:00","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-06-16"},{"id":7761,"accession_number":"0001104659-26-074338","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder voting results from Palvella Therapeutics' Annual Meeting held on June 16, 2026. The filing presents final vote tallies for six proposals: election of Class III directors (Jenkins, Davis, Doux), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, advisory frequency vote on compensation (approved annually), approval of equity plan amendment increasing authorized shares by 750,000, and adjournment authority. All proposals passed. This is material as it reflects stockholder decisions on governance, auditor selection, and equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T12:31:18.630711+00:00","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-06-16"}]}